Valuation
- Market cap
- 4,666,000
- Revenue TTM
- $0
- Net income TTM
- $-11,130,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 29,544
- Avg volume
- 25,387
- Day's range
- $2.31 – $2.75
- Shares out
- 1,897,000
- Stochastic %K
- 19%
- Beta
- 1.66
- Analysts
- Strong Sell
- Price target
- $27.75
Company profile
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyot...
Show more
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 972 9 799 6183
- Website
- https://www.neurosense-tx.com
- Address
- Building B, 11 HaMenofim Street, Herzliya, Israel
Latest news
No headlines yet.
